Mayo Clinic Laboratories scientists have developed a suite of BioPharma Diagnostics-specific oncology testing that is designed to provide answers for clinicians and aid in diagnosis and treatment.
As the significance of immunity in human disease is increasingly recognized, a thorough understanding of immune system complexities and fluctuations caused by a myriad of factors is integral for therapeutic optimization.
BioPharma Diagnostics and the Immune, Progenitor, and Cell Therapeutics (IMPACT) Lab have developed a novel profiling method that uses multi-parameter flow cytometry analysis to categorize patients based on immune system biomarkers. Our Clinical Immune Profile Service (CIPS) captures more than 100 different phenotypic parameters and has been proven to identify disease biomarkers and parameters associated with outcomes in multiple patient groups.
Comprehensive analysis
With the goal of categorizing patients based on a complete immune system assessment, CIPS offers a multi-parameter flow cytometry analysis. This approach provides a comprehensive view of the peripheral immune system at a single point in time, as well as measures and defines changes in peripheral circulating cell populations throughout the course of treatment. The identification of prognostic markers allows for acceleration of treatment strategies for new therapies. Reducing the dimensionality of the data enables rapid translation to clinical testing.
Checkpoint inhibitors and other immune modulators and cell therapies have become revolutionary in cancer treatment, yet patient response to these drugs is still varied. Predictors of response are necessary to identify best candidates for these therapies.
Immune profiling of pretreatment blood has been instrumental in determining phenotypic biomarkers that can be used as prognostic indicators of outcomes.
Checkpoint inhibitors CAR-T, MSC, and DC in clinical trial monitoring.
Disease stratification
Immune profiling can identify subgroups of patients based on similarities in immune phenotypes found using hierarchical clustering analysis.
Has been used in studies for Crohn’s disease, amyotrophic lateral sclerosis, and idiopathic pulmonary fibrosis populations.
Monitoring immune therapy response
Monitoring peripheral blood cells is an ideal method for measuring treatment-induced changes during therapy. Phenotypic differences observed at various points can aid in understanding immunological mechanisms of action.
Useful for studies associated with glioblastoma, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, as well as liver, lung, melanoma, and thyroid disease.
Disease pathology
Identifying phenotypes associated with specific diseases can help determine their nature and cause. Studying disease through initial infection, treatment, and recovery has been instrumental in understanding the body’s immune response to pathogens and viruses, as well as understanding how different pathologies can lead to similar symptoms.
Has been used in studies associated with COVID-19, viral hepatitis, thyroid disease.
Future analysis
As part of our immune monitoring service, we offer the collection and storage of ancillary samples in the form of plasma and blood pellets for future analysis.
Our 41 parameter MILLIPLEX® Human Cytokine/Chemokine Panel (EMD Millipore) is available in addition to clinical immune profiling.
